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Abstract 
Dysarthria is a motor speech disorder resulting from neurologic impairment affecting mainly 
the control and execution of movements related to speech production. Occurrence of 
dysarthria in adult age is commonly manifested as a consequence of degenerative disorder 
such as Parkinson's disease (PD), Huntington's disease (HD), multiple system atrophy (MSA), 
progressive supranuclear palsy (PSP) or cerebellar ataxia (CA). Interestingly, identification of 
specific deviant speech characteristics can provide important clues about the underlying 
pathophysiology and localization of neurological diseases. Speech may also serve as               
a valuable marker of disease onset or treatment efficacy. Therefore, the main aims of this 
doctoral thesis were (a) to design the feasible algorithms, methodologies or measurements that 
would be sensitive and accurate enough to capture pathological changes in speech, (b) to 
objectively quantify the effect of neurological disorder on speech production and (c) to relate 
the potentially observed speech changes to overall motor performance or medication doses in 
order to provide deeper insight into the pathophysiology of speech disturbances. 
 Several databases of PD, HD, MSA, PSP and CA patients as well as age-matched 
healthy controls were obtained. During recording, all participants were instructed to perform 
several speaking tasks such as sustained phonation, fast syllable repetition, reading passage or 
monologue. In addition, various clinical information about patient's motor skills, cognitive 
abilities or medication doses was available. The acoustic analyses were carried out to provide 
quantitative objective evaluation of speech performances. Statistical analyses were applied to 
search for possible group differences or correlations between speech and clinical metrics. 
 The results of this doctoral thesis are presented in the form of nine peer-reviewed 
journal papers. In summary, we managed to objectively quantify the effect of neurological 
disorder on speech production in PD, HD, MSA, PSP and CA patients. Furthermore, we 
proved that the separation of patients from healthy controls based solely on speech is possible.                    
The differentiation among several types of parkinsonian disorders is also possible as we were 
able to discriminate between MSA/PSP and PD with 95 % accuracy and between PSP and 
MSA subjects with 75 % accuracy. In addition, a number of correlations were found between 
clinical and speech characteristics. Considering PD, an adverse effect of levodopa on speech 
fluency was found in PD patients after 3-6 years of taking medication. On the other hand, we 
found improved or maintained speech performances (related mainly to consonant and vowel 
articulation, pitch variability and number of pauses) in two-thirds of those PD patients 
whereas speech deteriorated only in one-third; indicating general positive effect of long-term 
dopaminergic therapy on dysarthria in early stages of PD. In conclusion, objective acoustic 
analysis of motor speech disorders can significantly contribute to early and correct diagnosis 
of the particular disorder and provide more insights into underlying pathophysiology of such 
diseases. 
Keywords 
Speech impairment; Dysarthria; Acoustic analysis; Parkinson's disease; Huntington's disease; 
Atypical parkinsonian syndromes; Levodopa; Contrastive stress; Dysfluency; Voice onset 
time; Vowel articulation. 
V 
Abstrakt 
Dysartrie je porucha hlasu a řeči vznikající v důsledku poškození funkce části mozku, která je 
zodpovědná zejména za řízení a provádění pohybů souvisejících s tvorbou řeči. Dysartrie se            
v dospělosti běžně vyskytuje jako důsledek degenerativních onemocnění, mezi která patří       
i Parkinsonova nemoc (PN), Huntingtonova nemoc (HN), mnohočetná systémová atrofie 
(MSA), progresivní supranukleární obrna (PSO) nebo cerebelární ataxie (CA). Rozpoznání       
a klasifikace specifických řečových charakteristik souvisejících s dysartrií může poskytnout 
důležité informace o patofyziologii a lokalizaci neurologických onemocnění. Hodnocení míry 
poškození řeči pak může též sloužit jako cenný ukazatel pro stanovení doby nástupu nemoci 
či účinnosti léčby. Hlavní cíle této disertační práce jsou: (a) navrhnout vhodné algoritmy, 
metody a měření, které by byly dostatečně citlivé a přesné, aby zachytily patologické změny        
v řeči, (b) objektivně kvantifikovat vliv neurologických poruch na řečový projev a (c) hledat 
souvislosti mezi pozorovanými změnami v řeči a celkovým motorickým stavem pacienta        
či medikací, kterou užívá, za účelem hlubšího porozumění patofyziologii poruch řeči. 
V rámci dizertace bylo pořízeno několik databází PN, HN, MSA, PSO a CA pacientů 
a zdravých kontrol odpovídajícího věku. V průběhu nahrávání byli všichni účastníci studie 
požádáni o provedení několika řečových úloh jako je prodloužená fonace, rychlé opakování 
slabik, přečtení úryvku textu nebo vyprávění krátkého monologu. Dále byly pořízeny 
záznamy s různými klinickými informacemi o stavu motorických či kognitivních schopností 
pacienta nebo dávkách užívaných léků. Objektivní kvantitativní hodnocení řeči bylo 
provedeno s pomocí akustických analýz. Statistické analýzy byly použity k hledání možných 
rozdílů mezi skupinami či korelací mezi řečovými a klinickými charakteristikami. 
 Výsledky této disertační práce jsou prezentovány v podobě devíti IF publikací. Vliv 
neurologické poruchy na produkci řeči se nám podařilo objektivně kvantifikovat u všech 
zkoumaných nemocí včetně PN, HN, MSA, PSO a CA. Dále se ukázalo, že oddělení pacientů 
od zdravých kontrol pouze na základě nahrávky řečového projevu je možné. Taktéž jsme 
prokázali, že i diferenciace mezi několika velmi podobnými nemocemi parkinsonského typu 
je možná. S použitím akustických analýz jsme byly schopni rozlišit mezi MSA/PSO a PN       
s přesností 95 % a mezi PSO a MSA s přesností 75 %. Dále jsme objevili řadu korelací mezi 
klinickými a řečovými charakteristikami. Nepříznivý účinek levodopy na plynulost řeči byl 
nalezen u pacientů s PN po 3-6 letech užívání tohoto léku. Na druhé straně jsme pozorovali 
zlepšení nebo alespoň zachování kvality řečového projevu (související zejména s přesností 
artikulace souhlásek a samohlásek, variabilitou výšky hlasu a počtem pauz) u 2/3 těchto PN 
pacientů, zatímco řeč se zhoršila pouze u 1/3. Tyto nálezy naznačující celkový pozitivní 
účinek dlouhodobého užívání levodopy na dysartrii v brzkých stádiích PN. Závěrem lze říci, 
že objektivní akustická analýza poruch řeči může významně přispět ke včasné a správné 
diagnóze dané nemoci a také přispět k hlubšímu porozumění patofyziologii těchto chorob. 
Klíčová slova 
Poruchy hlasu a řeči; Dysartrie; Akustické analýzy; Parkinsonova choroba; Huntingtonova 
nemoc; Atypické parkinsonské syndromy; Levodopa; Kontrastivní větný důraz; Neplynulost 
řeči; Artikulace souhlásek; Artikulace samohlásek. 
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1. Introduction 
 
Speech is a unique, complex, dynamic motor activity through which we express thoughts and 
emotions and respond to and control our environment (1). It is one of the most powerful tools 
possessed by the human species, and it contributes enormously to the character and quality         
of a person's life. In fact, communication is central to everything we do. It affects who we are, 
how we learn, how we interact with other people or how successful we are at work. Speech 
requires the integration of numerous activities including cognitive-linguistic processes, motor 
speech planning and programming, and neuromuscular execution (1). Thus, the large span           
of brain functions may be surveyed with analysis of speech functions, explaining why they 
have become extensively studied in both basic research as well as clinical practice. 
 
1.1. Motivation 
 
 The elderly population is growing fast all over the world and, as a consequence,       
the number of elderly subjects with speech/language disorders has also increased rapidly (2). 
Occurrence of voice and speech disorders in adult age is commonly manifested as                       
a consequence of degenerative, traumatic, vascular, infectious, demyelinating or other 
diseases. Among these, various neurological disorders such as Parkinson's disease (PD), 
Huntington's disease (HD), multiple system atrophy (MSA), progressive supranuclear palsy 
(PSP), cerebellar ataxia (CA), Lewy body dementia or amyotrophic lateral sclerosis are 
responsible for development of dysarthria in approximately 50 % of all etiologies (1).  
 Interestingly, it has been previously demonstrated that abnormalities of speech in some 
of these disorders may appear several years before the diagnosis is established (3, 4, E1) and 
can be even the earliest indicator of the disease (1, 5). In addition, identification of specific 
deviant speech characteristics can provide important clues about the underlying 
pathophysiology and localization of neurological diseases (1). Speech may also serve as          
a valuable marker of treatment efficacy (A1, A4), disease progression (6, 7) or disease 
severity (8). 
 Voice and speech disorders can be investigated by perceptual, acoustic, physiologic           
or visual imaging methods. Among these, perceptual methods are presumably the most 
commonly used being the gold standard for clinical differential diagnosis, judgements                 
of severity, many decisions about management, and the assessment of meaningful temporal 
changes (1). However, at the same time, they are subjective in nature, difficult to quantify and 
may significantly differ when performed by two independent speech specialists. In addition, 
perceptual assessment can hardly be used to capture speech changes in early stages of disease 
(A8) where dysarthria is often non-perceptible or to capture slight alterations in speech due to 
various effects such as medical interventions (A4). See Figure 1 for an example of perceptible 
and non-perceptible alterations of speech that might be observed in phonation of patients with 
HD. 
 Contrary, acoustic methods can visually display and objectively quantify many 
temporal components of speech signals. To this extent, acoustic analysis of speech has          
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the unique potential to provide objective, sensitive, cheap and relatively easy to administer 
method to precisely assess the degree of speech impairment (9).  
 
Figure 1: The example of perceptible and non-perceptible alterations in speech. A) Healthy phonation 
of vowel /a/. B) Non-perceptible changes in pathological phonation of vowel /a/; the frequency                
of vocal folds vibration drops to half of its original value for a short period of time. C) Perceptible 
changes in pathological phonation of vowel /a/; the vibration of vocal folds is vanished for a short 
period of time. 
 
1.2. Organisation of the thesis 
 
 Presented doctoral thesis is submitted as a collection of nine author’s main research 
papers (A1-A8, B1) related to the topic of the doctoral thesis accompanied by                       
the integrating text1. 
 The particular organisation of the thesis is as follows. The basic notions and facts 
regarding the topic of the thesis are described and the relevant literature is provided                   
in Chapter 2. In Chapter 3 the goals of the thesis are clearly defined. Subsequently,                     
the general approach considering methods used is explained in Chapter 4 and the results           
in  the form of nine main author’s articles (A1-A8, B1) are shortly introduced in Chapter 5. 
Furthermore, the summary of the achieved results and their contributions to the aims              
of the doctoral thesis are explicitly stated in Chapter 6. Finally, a conclusion is made               
in Chapter 7 and possible future directions suggested in Chapter 8. 
 

1 This format of the doctoral thesis is approved on the Faculty of Electrical Engineering, Czech Technical 
University in Prague by the Dean's directive from the 1st November 2014.  
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2. State of the art 
 
This chapter presents an overview about the current stage of the problem and the literature 
connected with the topic of the doctoral thesis. In the first part, some basic information about 
motor speech disorders, methodology for categorizing of dysarthria subtypes and breakdown 
on selected degenerative diseases leading to development of dysarthria are provided.                     
In the second part, the basic medical interventions related to treatment of PD, HD, PSP, MSA 
or CA are introduced including pharmacological and surgical interventions, physiotherapy 
and speech therapy. 
 
2.1. Motor speech disorders 
 
Motor speech disorders (MSD) can be defined as speech disorders resulting from neurologic 
impairments affecting the planning, programming, control or execution of speech (1). MSD 
include the dysarthria and apraxia of speech. While both dysarthria and apraxia of speech are 
neurologic in origin, resulting from damage to central nervous system, dysarthria is a disorder 
of movement control and execution whereas apraxia of speech impairs especially                  
the processes of planning or programming of movements of essentially normal strength, 
speed, and coordination of the speech musculature (1, 10). Among acquired neurologic 
communication disorders, dysarthria accounts for about 53.0 % of the primary diagnoses and 
it is far more prevalent than any other category including aphasia (25.8 %), nonaphasic 
cognitive-communication disorders (16.8 %) or apraxia of speech (3.9 %) (1). 
  
2.1.1. Dysarthria 
 
Dysarthria is a speech disorder that reflects abnormalities in the strength, speed, range, 
steadiness, tone or accuracy of movements required for the breathing, phonatory, resonatory, 
articulatory, or prosodic aspects of speech production (1). Dysarthria is associated with one    
or more sensorimotor abnormalities including weakness, spasticity, slowness or 
incoordination of the musculature used to produce speech. Dysarthria occurs with 
considerable frequency in individuals with PD, multiple sclerosis, traumatic brain injury, 
small stroke, cerebellar diseases, amyotrophic lateral sclerosis or cerebral palsy (11-14). 
Voice and speech disorders have also been recognised to be one of the first manifestations in 
persons with HD, PD or amyotrophic lateral sclerosis (1, 5, 15, 16). 
 Generally, the dysarthrias have global, rather than focal, effect on the speech 
production affecting multiple dimensions of spoken language, i.e. phonation, respiration, 
articulation, prosody or resonance at the same time (10, 17, 18). While perceptual methods are 
still considered to be a gold standard for evaluation of dysarthria (1), significant progress has 
been made in description of various dysarthria subtypes using acoustic analyses (14, 19, 20) 
and physiological methods (21).  
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2.1.2. Categorizing of dysarthria subtypes 
 
The modern classification of the dysarthrias rests largely on two articles published three 
decades ago (22, 23). In these studies (22, 23), Darley et al. investigated large sample              
of speakers with dysarthria resulting from different neurological conditions using auditory-
perceptual based evaluation of voice and speech deficits. Darley et al. (22, 23) noted that 
constellation of specifically affected speech dimensions is related to localization in the 
nervous system and typically reflects the presumed underlying pathophysiology. Based on 
these findings, authors defined seven dysarthria subtypes including flaccid, spastic, ataxic, 
hypokinetic, hyperkinetic, unilateral upper motor neuron and mixed (1, 22, 23); see Table 1 
for more details. 
Table 1: Breakdown of dysarthria subtypes. 
Dysarthria subtype   Localization  Pathophysiology 
Flaccid  Lower motor neuron  Weakness 
Spastic  Bilateral upper motor neuron  Spasticity 
Ataxic  Cerebellum  Incoordination 
Hypokinetic  
Basal ganglia circuit              
(substantia nigra)  Rigidity, bradykinesia 
Hyperkinetic  
Basal ganglia circuit                 
(putamen or caudate)  Involuntary movements 
Unilateral upper motor neuron  
Unilateral upper motor 
neuron  
Upper motor neuron weakness, 
incoordination or spasticity 
Mixed   More than one  More than one 
 
 For each dysarthria subtype the distinctive cluster of deviant speech dimensions was 
identified. It should be noted that the classification method itself covers approximately         
50 different perceptually distinguishing speech dimensions. See Table 2 for example of 
deviant speech dimensions manifested in each of four fundamental dysarthria subtypes. 
Although there are currently several more elaborated perceptual scales (for example 
Dysarthria Profile or Frenchay Dysarthria Assessment) (14), the Darley's approach remains 
landmark achievement and it is still fundamental for clinical practice. 
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Table 2: Breakdown on clusters of deviant speech dimensions in individual dysarthria subtypes 
according to studies (1, 22, 23). The list includes only certain selected dimensions. 
Deviant speech dimensions   Dysarthria subtype Spastic Ataxic Hypokinetic Hyperkinetic
Harshness   ↑↑  −  −   ↑ 
Slow rate ↑↑ ↑ − ↑ 
Pitch breaks   ↑↑  −  −   ↑ 
Slow and regular AMRs ↑↑ − ↑ − 
Excess and equal stress   ↑  ↑↑  −   − 
Distorted vowels − ↑↑ − ↑↑ 
Excess loudness variations   −  ↑↑  −   ↑↑ 
Prolonged phonemes − ↑ − ↑ 
Reduced stress   −  −  ↑↑   − 
Monoloudness ↑ − ↑↑ − 
Inappropriate silences   −  −  ↑↑   ↑ 
Increased overall rate − − ↑↑ − 
Reduced loudness   −  −  ↑↑   − 
Voice tremor − − − ↑↑ 
Prolonged intervals   −  −  −   ↑↑ 
Intermittent hypernasality − − − ↑↑ 
Echolalia   −  −  −   ↑↑ 
Captions: AMR alternating motion rate; ↑ particular deviant speech dimension that may or may not be 
preserved but it is not distinguishing by itself; ↑↑ particular deviant speech dimension that is 
prominent or distinguishing. 
 
2.1.3. Selected degenerative diseases leading to development of dysarthria 
 
Parkinson’s disease 
PD is a neurodegenerative disorder characterized by progressive loss of dopaminergic neurons 
in part of the brain called substantia nigra, affecting 1.6 % of persons over the age of 65 years 
(24). It commonly begins in middle to late decade of life and the life expectancy after 
diagnosis is about 15 years. Its occurrence is usually sporadic, but nearly one third of people 
with two or more affected first-degree relatives are likely to acquire the disease (1).                   
The cardinal motor signs of PD are resting tremor, bradykinesia, rigidity and postural 
instability. In addition, many patients with PD develop other motor or non-motor deficits such 
as autonomic dysfunction, cognitive decline, depressions, sleep alterations or speech and 
swallowing impairment (12, 25, 26). Currently, there is no available causal cure, although 
medical interventions, including pharmacological and surgical ones, offer alleviation of some 
symptoms, especially in the early stages of the disease. 
 Up to 90 % of individuals with PD developed an alteration of speech termed                  
as hypokinetic dysarthria (17, 27). Hypokinetic dysarthria might be one of the earliest 
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symptoms and exhibits even several years before the diagnosis is established (5, 28). 
Commonly reported speech deficits experienced by PD individuals include monoloudness, 
monopitch, reduced stress, imprecise articulation, variability of speech rate, a breathy, harsh 
voice, dysfluency, voice tremor, and other manifestations that lead to overall reduced speech 
intelligibility (1, 22). Although the PD patients ordinarily exhibit pure hypokinetic dysarthria, 
the emergence of various hyperkinetic features may appear in later stages as a consequence of 
ON-OFF fluctuations related to long-term usage of high dosage of dopaminergic medication 
(29). 
 
Multiple system atrophy 
Degenerative diseases that include but go beyond the manifestations of parkinsonism are 
known as atypical parkinsonian syndromes (APS). However, in contrast to PD, APS respond 
poorly to levodopa (L-dopa) treatment and exhibit more rapid disease progression (30, 31).         
In particular, APS cover MSA, PSP, Lewy body dementia and corticobasal degeneration (30). 
An estimated prevalence of MSA is about 30 persons per 100,000 among people older than 65 
years (32). MSA is manifested by various combination of autonomic, cerebellar, parkinsonian 
and pyramidal features (33).  
 MSA patients typically develop mixed dysarthria with combination of hypokinetic, 
ataxic and spastic components as a result of more widespread neural atrophy including 
damage in the basal ganglia circuit and cerebellum (34). Indeed, the previous study (34) 
investigating 46 MSA patients by perceptual speech analysis reported presence of mixed 
dysarthria in two-thirds of subjects. Specifically, hypokinetic components were found to be 
predominated in 48 % of patients, whereas ataxic components predominated in 35 %           
and spastic in 11 % (34). With respect to particular speech dimensions voice perturbations, 
slow and variable alternating motion rates, imprecise consonant articulation and increased 
loudness were documented to be most affected (35, 36). 
 
Progressive supranuclear palsy 
PSP is a neurodegenerative disorder of unknown origin with disease onset in middle to late 
age that belongs among APS. The incidence of disease is estimated as 40 persons per 100,000 
in population over the age of 65 years, and the average life expectancy is about 5.3 years after 
disease onset (32, 37). Characteristic clinical features of PSP are supranuclear gaze palsy, 
frequent falls, bradykinesia, axial rigidity, cognitive decline and communication disorders 
(38, 39). 
 In accordance with MSA, PSP patients also commonly evolve mixed dysarthria with 
combination of all hypokinetic, ataxic and spastic components mainly due to damage            
in the basal ganglia circuit and corticobulbar pathways (40). In compliance with MSA (34), 
the research focused on examination of 44 PSP patients using oral motor assessment and 
perceptual speech analysis revealed mixed dysarthria in two-thirds of PSP subjects. 
Nevertheless, the dysarthria in PSP patients, contrary to MSA, was characterized                  
by predominated spastic components in 50 % of patients, while hypokinetic components were 
most severely affected in 34 % of subjects and ataxic in 14 % of subjects (40). Interestingly, 
dysarthria in PSP was also characterized by stuttering-like behaviour in 31 % of individuals 
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(40). As stuttering-like behaviour was not observed in MSA, it seems to be specific only        
for PSP (34, 40).  
 
Huntington’s disease 
HD is an autosomal-dominant inherited neurodegenerative disorder caused by an expansion   
in the number of CAG repeats on the short arm of chromosome 4p16.3 in the Huntington gene 
(41), which is characterized by uncoordinated body movements, psychological dysfunction 
and a reduction in cognitive decline resulting in dementia. The prevalence of HD is estimated 
to be about 4-8 subjects for 100,000 people (42, 43). From a clinical perspective, HD is 
primarily manifested by involuntary movements termed as chorea, which may be 
accompanied by bradykinesia, motor impersistence, and deficits in movement planning, 
aiming, tracing and termination (44).   
 Voice and speech disorders, known as hyperkinetic dysarthria, are a common sign of 
HD, developing in more than 90 % of HD patients in the course of the disease. Based upon        
30 speakers with various underlying choreatic movement disorders, Darley et al. (22,23) 
perceptually defined the characteristic patterns of hyperkinetic dysarthria mainly by the 
presence of imprecise consonants, prolonged intervals, variable rate, monopitch, harsh voice, 
inappropriate silence, distorted vowels, and excess loudness variations. Subsequently, only       
a few studies have provided more accurate description of hyperkinetic dysarthria in patients 
with genetically confirmed HD documenting mainly the abnormalities in voice function (45) 
and speech timing (16, 46, 47). 
 
Cerebellar ataxia 
Sporadic and hereditary CAs are associated with progressive degeneration of the cerebellum 
and its afferent and efferent pathways. Spinocerebellar ataxia is a rare, autosomal-dominant 
neurological disorder with an estimated prevalence of approximately 3-4 cases per 100,000 
individuals (48). On the contrary, idiopathic late-onset cerebellar ataxia refers to a group of 
sporadically occurring degenerative diseases of the cerebellum and the brainstem of unknown 
etiology (49). Despite differing pathogenesis, pathologic changes in these disorders are very 
similar with consistent involvement of the cerebellum, which is essential for posture and fine 
motor control. From a clinical perspective, CA is dominated by progressive gait ataxia 
characterized by staggering gait, increased step width, incorrect foot placement, increased 
variability in stride length and poor inter-limb coordination resulting in loss of balance and       
a high risk of falling (50). 
 Speech impairment associated with CA is assumed to be dominated by ataxic 
dysarthria, but because multiple portions of the motor system can be involved, combination 
with other dysarthria subtypes is possible (1). The first complex description of ataxic 
dysarthria was based on of speech samples elicited from 30 patients with etiologically 
different cerebellar disorders (22). Prosodic modulations such as excess and equal stress         
and excess loudness variations as well as articulatory features including irregular breakdowns, 
distorted vowels, prolonged phonemes and slow and irregular alternating motion rates were 
perceptually identified to be distinctive for ataxic dysarthria (22). Especially, rhythmical 
irregularities during fast repetitive productions of multiple syllables have been assumed          
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to be a specific oral motor feature of ataxic impairment (1, 51). Later descriptions of ataxic 
dysarthria based primarily on objective kinematic and acoustic methods in spinocerebellar 
ataxia patients confirmed previous findings and emphasized the role of imprecise consonant 
and vowel articulation (52-54). 
 
2.2. Effect of medical interventions on dysarthria 
 
A number of approaches may be used to manage dysarthria. These treatment methods include 
mainly various forms of speech therapy, however, positive effect might also be induced        
by some of the pharmacological or surgical interventions commonly used for treatment          
of neurodegenerative diseases; either intended or as a side-effect. The influence of other 
interventions such as physiotherapy remains generally unknown. 
  In the following section, especially treatment approaches related to management         
of hypokinetic dysarthria of PD are reviewed as PSP, MSA and HD patients are not principal 
targets with respect to speech therapy due to rapid disease progression of these diseases. Some 
comments are also noted with respect to CA patients manifesting ataxic dysarthria. 
 
2.2.1. Speech therapy 
 
The speech therapy approaches for treatment of hypokinetic dysarthria are based either          
on behavioural treatment (conscious training to strengthen muscles involved with 
coordination of respiration, phonation and articulation) or on the use of devices and 
biofeedback (55). In addition, a novel approaches requiring motor learning and increased 
sensory awareness such as Lee Silverman Voice Treatment (LSVT) have been introduced. 
The commonly used devices include voice amplifier, delayed auditory feedback, a wearable 
intensity biofeedback or masking noise device. The main goal of these devices is to improve 
patient's intelligibility through increment in vocal loudness, therefore their positive effect           
is usually directly limited to their usage and diminished when not worn (56, 57).  
 Currently, probably the most widely used speech therapy for PD is LSVT, which was 
developed by Ramig et al. (58). The LSVT focuses on increasing of both respiratory effort 
and vocal fold adduction during therapy lasting 16 sessions per one month with the emphasis 
on recalibration of speech effort so that speakers appreciate the level of effort needed to speak 
(59). Positive outcomes have been documented at the level of speech intelligibility, pitch 
range, articulation rate, facial expression and swallowing (60, 61). Furthermore, unlike other 
respiratory-based speech therapy LSVT is supported by evidence of maintained enhancements 
following 24 months after the end of therapy (62). In particular, higher level of loudness             
and pitch variability was observed immediately as well as 24 months after therapy in speaking 
tasks of sustained phonation, reading passage and monologue (62).  
 
2.2.2. Pharmacological interventions 
 
Many different drugs have been developed to treat PD including L-dopa and dopamine 
agonists. These drugs replace and enhance the level of dopamine in the brain of persons          
with PD. Parkinsonian patients have usually a favourable response to dopaminergic therapy  
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at the start of the treatment leading to temporarily diminishing of most cardinal motor 
symptoms. However, the motor ON-OFF fluctuations may occur after several years                       
of dopaminergic replacement therapy, i.e. motor improvements in the ON periods begin to 
wane and become shorter in duration while the person with PD experience severe disability 
due to prolonged reappearance of PD symptoms during OFF periods (63). These fluctuations 
lead to necessity to increase L-dopa dosages. 
 While the beneficial effect of dopaminergic therapy on the principal motor 
manifestations of PD has been clearly documented, its effect on overall speech performance 
remains inconclusive with mixed and contradictory results (55, 64). These ambiguous 
findings have been reported considering both long-turn as well as short-term (comparison ON 
versus OFF condition) effect of dopaminergic therapy. In general, a number of former reports 
based on perceptual analyses have reported an improvement of speech performance under 
dopaminergic therapy, while most of the recent studies found no significant treatment effects 
(55, 64). Such discrepancies across previous studies may be attributable to participant related 
differences (size of the database, dosage of medication, speech severity, disease severity and 
motor phenotype) or various methodological settings (64). In fact, most of the studies have 
focused on only particular aspects of speech and have not tried to assess complex speech 
behaviour, whereas parkinsonian patients may manifest varied deficits across individual 
measures and characteristics (17, 65). 
 
2.2.3. Surgical interventions 
 
Deep brain stimulation (DBS) is currently the most commonly used surgical procedure         
for treatment of movement and affective disorders. During surgery implantation of a medical 
device called a neurostimulator, which sends electrical impulses through implanted electrodes 
to specific parts of the brain, is performed. Stimulators are most frequently implanted            
in subthalamic nucleus (STN), but also other targets such as globus palllidus interna (GPi), 
caudal zona incerta or ventralis intermediate nucleus can be utilized. DBS in select brain 
regions provides therapeutic benefits for patients with otherwise pharmacologic treatment-
resistant movement disorders such as PD, HD, dystonia, essential tremor  or Tourette 
syndrome. DBS has not been developed specifically to improve speech, although 
improvements have been occasionally noted; for review see (66).   
 A vast body of evidence have proven the positive effect of STN-DBS on cardinal 
motor symptoms in PD. However, the effect of STN-DBS on voice and speech has been 
reported to be variable or even adverse (55, 66). According to simple clinical perceptual 
evaluation, a meta-analysis of 37 cohorts comprised of 921 patients reported an incidence          
of dysarthria after STN-DBS in 9.3 % of cases (67). On the other hand, beneficial effect             
of STN-DBS on dysarthria have been documented at least in individual patients, although          
the improvements were much less pronounced than that on limb movements and tend to 
decrease in the long term (66). It has been also suggested that STN-DBS has a differential 
impact on different speech subsystems with the potential to ameliorate phonation, however,         
at the cost of a deterioration of articulatory capacities leading to a reduction of overall speech 
intelligibility (66). 
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 The effect of other DBS potential targets on parkinsonian speech has only scarcely 
been investigated so far. However, based on previous results that compared the effect of           
GPi-DBS and STN-DBS using identical methodology, the negative effect on speech 
production appears to occur less frequently under GPi-DBS than under STN-DBS (68).  
 
2.2.4. Physiotherapy 
 
Considering ataxic dysarthria, efforts to increase physiologic support by increasing muscle 
strength are generally unnecessary for ataxic speakers, and there is no compelling evidence         
to support their effectiveness to the disorder (1). Similarly, surgical or pharmacologic 
interventions do not provide any relieve of dysarthria. Therefore, the treatment approaches  
for ataxic dysarthria are usually focused on improving or compensating for problems related 
to motor control and coordination (1). Particularly, the training of coordination of oral 
movements may be effective (69). On the other hand, one might expect that patients could 
also benefit from physiotherapy focused on enhancement of body balance and trunk stability 
due to several reasons. Firstly, it has been documented that good postural alignment               
is an important element for the optimization of vocal function (70). Another mechanism may 
be connected to increased proprioceptive awareness, especially related to better perception        
of articulatory position and muscle strength. Finally, the principle of transference in neural 
plasticity states that plasticity following training in one function may enhance related 
behaviours (71). Nevertheless, the effect of physiotherapy targeted on improvement of body 
stability on speech has not been investigated so far. 
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3. Goals of the thesis 
 
The presented cumulative dissertation comprises nine peer-reviewed journal papers (A1-A8, 
B1) and several other publications (C1, D1-D10). As a result, there might be a number of 
various aims stated, some of which are mentioned below. In general, the aims are                  
of two-types: (a) overlapping, interrelated aims belong to several papers, and (b) specific, 
particular aims strongly related to the topic of the presented article. The goals of the doctoral 
thesis have been defined as follows: 
General goals (aim 1-4)  
1) To objectively quantify the effect of neurological disorder on speech production. 
 
2) To design the feasible algorithms, methodologies or measurements that would be 
sensitive and sufficiently accurate to capture pathological changes presented in 
particular speech dimensions. 
 
3) To relate the potentially observed speech changes to overall motor performance             
or medication doses in order to provide deeper insight into the pathophysiology           
of speech disturbances. 
 
4) To critically discuss the revealed findings in the context of wide state-of-the-art. 
Specific goals (aim 5-10) 
5) To determine specific dysarthric patterns and estimate their reliability in 
differentiating between PD, PSP and MSA patients. 
 
6) To search for possible early markers of PD that would separate healthy control (HC) 
speakers from de-novo PD patients. 
 
7) To design innovative measurement that would reflect the effect of all main acoustic 
cues exploited during stress production. 
 
8) To design methodology for evaluation of imprecise vowel articulation based on 
spontaneous speech such as monologue. 
 
9) To investigate the effect of different speaking tasks on assessment of vowel 
articulation. 
 
10) To examine the effectiveness of a 2-week intensive coordinative motor training             
on speech production in CA patients. 
 
 
 
12 
 
4. Methods  
 
Although the particular methods used for speech evaluation are strongly dependent on the aim 
of each study, the general approach might be described in the following four steps: (1) 
selection of available population sample for given aim and defining the inclusion/exclusion 
criteria, (2) recording of the participants and speaking tasks, (3) selection or development of 
suitable acoustic features for evaluation of voice and speech performances, (4) statistical 
analysis. See Figure 2 for schematic overview of methods applied to evaluate MSD. 
 
 
 
Figure 2: Schematic overview of methods applied to evaluate MSD including recording of participant, 
digital processing of speech signal and statistical assessment/classification experiment. 
 
4.1. Recording of the participants and speaking tasks 
 
Speech samples were recorded in a quiet room with a low level of ambient noise using 
recorder and an external condenser microphone. The signals were sampled at 48 kHz           
with 16-bit resolution. Recordings were obtained during one session with a speech specialist 
who conveyed instructions to the subjects. There were no time limits during the recordings.          
All participants were asked to repeat their performance at any time if they or the examiner 
were not fully satisfied with their initial attempt.  
Investigation protocol consisted from various kind of speaking tasks such as:                  
(a) sustained phonation of the vowel /a/ as long and stable as possible repeated two times,         
(b) fast repetition of syllables /pa/-/ta/-/ka/ at least 10 times per one breath repeated two times, 
(c) reading of the Czech phrase “Kolik mate ted u sebe asi penez.”(How much money do you 
have in your wallet?) per one breath repeated five times, (d) reading of standardized passage 
composed of 80 words, (e) reading of a short block of text with denoted words were unnatural 
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emphasize should be placed, (f) reading of cards with 18 different words composed to assess 
consonant articulation repeated two times or (g) a monologue lasting at least 2 minutes         
on given topics including family, work, childhood or interests.  
The exclusion criteria for HC participants were the history of neurological                  
or communication disorders, the serious problems with respiration or hearing or the suspicion 
of memory deficits. The inclusion and exclusion criteria for patients were different reflecting 
the specific aims of particular studies (A1-A8, B1).  
 
4.2. Acoustic evaluation of voice and speech performances 
 
The speech characteristics were examined using commercial program environments, namely 
Praat and Multi-Dimensional Voice Program, or original algorithms developed in Matlab        
as a part of our previous (17, 72) or currently presented studies (A3, A5, A7, B1). Several 
acoustic measurements were applied to investigate alterations in various speech dimensions. 
Both standard as well as innovative measurements were used. Some of them are mentioned        
in the following paragraph. 
To assess voice quality, we investigated jitter, shimmer, harmonic-to-noise ratio, 
degree of pitch breaks, or pitch variability extracted from sustained phonation. With respect to 
vowel articulation, vowel space area, formant centralization ratio or vowel articulation index 
were computed based on analyses of the first and second formant frequencies using 
monologue and reading passage. The consonant articulation was assessed by measuring 
voice onset time, diadochokinetic regularity or diadochokinetic rate using fast repetition of 
/pa/-/ta/-/ka/ syllables. To evaluate aerodynamic efficiency, maximum phonation time of 
sustained phonation was measured. To capture problems with prosody, the ability to modulate 
pitch and loudness was surveyed computing variability of fundamental frequency and 
intensity using reading text and monologue. Considering timing problems, number of pauses 
lasting more than 60 ms, pause time percentage relative to total speech time or articulation 
rate was measured. To determine reduced ability to express word stress, average value of 
pitch and intensity contour, duration of word or stress pattern index were elicited.                
With respect to dysfluency, the percentage of within- and between-word dysfluencies was 
determined based on reading text and monologue using the Lidcombe Behavioral Data 
Language of stuttering taxonomy (73). 
 
4.3. Statistical analysis 
 
Individual parameters were firstly assessed using Kolmogorov-Smirnov test for testing           
of normality of data distribution. On the basis of these tests, the alternative parametric or  
non-parametric tests were chosen. For normally distributed data, we used the t-test or analysis 
of variance to assess group differences and Pearson analysis to evaluate correlations between 
speech and other clinical data. In case of other distributions, the nonparametric Wilcoxon test 
was used to determine group differences and Spearman correlation to search for relationships 
between speech and other clinical metrics. Moreover, we applied where appropriate modern 
methods of statistical decision tools (e.g., support vector machine, minimax task) or 
regression analysis. 
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5. Results and Papers 
 
This chapter covers the main results of the author’s research related to the topic of                    
the presented thesis in the form of eight articles (A1-A8) published or accepted                        
for publication in peer-reviewed journals and one additional manuscript (B1) submitted           
for review process; author of this dissertation is the first author of four papers (A1-A3, B1).           
For each article a short summary is inserted including information about authors and their 
affiliations, journal, year of publication, journal statistics and abstract. 
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5.1. Speech changes after coordinative training in patients with cerebellar ataxia:           
a pilot study (A1) 
 
Authors and affiliations: 
Tereza Tykalová1, Mariana Pospíšilová2, Roman Čmejla1, Jaroslav Jeřábek3, Pavel 
Mareš4, Jan Rusz1 
1Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical 
University in Prague 
2Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles 
University in Prague and Motol University Hospital 
3Department of Neurology, 2nd Faculty of Medicine, Charles University in Prague and 
Motol University Hospital 
4Institute of Physiology, Academy of Sciences of the Czech Republic 
 
Journal, year of publication: Neurological Sciences, 2016 
 
Journal statistics according to the Journal Citation Report® (2015): 
Impact factor: 1.783 
5-year impact factor: 1.494 
Category: Clinical neurology / Neurosciences 
Quartile in category: Q3 / Q3 
 
Abstract: 
Although rehabilitative training is a necessary adjunct in the management of gait ataxia, 
it remains unknown whether the possible beneficial effect of intensive coordinative 
training may translate to activities of daily living, which are closely connected          
with postural alignment. The aim of the present study was to examine the effectiveness          
of a 2-week intensive coordinative motor training on speech production. Speech and 
motor performances in a cohort of ten individuals with cerebellar degeneration were 
examined three times; before the introduction of training, directly and 4 weeks after          
the last training session. Each patient was instructed to perform a speaking task of fast 
syllable repetition and monologue. Objective acoustic analyses were used to investigate 
six key aspects of speech production disturbed in ataxic dysarthria including accuracy                  
of consonant articulation, accuracy of vowel articulation, irregular alternating motion 
rates, prolonged phonemes, slow alternating motion rates and inappropriate 
segmentation. We found that coordinative training had a mild beneficial effect                
on speech in cerebellar patients. Immediately after the last training session, slight 
speech improvements were evident in all ten patients. Furthermore, follow-up 
assessment performed 4 weeks later revealed that 90 % of the patients showed better 
speech performance than before initiation of the therapy. The present study supports 
evidence that the intensive rehabilitative training may positively affect finemotor 
movements such as speech in patients with cerebellar ataxia. 
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5.2. Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: 
a longitudinal study (A2) 
 
Authors and affiliations: 
Tereza Tykalová1, Jan Rusz1,2, Roman Čmejla1, Jiří Klempíř2, Hana Růžičková2, Jan 
Roth2, Evžen Růžička2 
1Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical 
University in Prague 
2Department of Neurology and Centre of Clinical Neuroscience, First Faculty of 
Medicine, Charles University in Prague 
 
Journal, year of publication: Journal of Neural Transmission, 2015 
 
Journal statistics according to the Journal Citation Report® (2014): 
Impact factor: 2.402 
5-year impact factor: 2.732 
Category: Clinical neurology / Neurosciences 
Quartile in category: Q2 / Q3 
 
Abstract: 
Although speech dysfluencies have been hypothesized to be associated with abnormal 
function of dopaminergic system, the effects of dopaminergic medication on speech 
fluency in Parkinson’s disease (PD) have not been systematically studied. The aim          
of the present study was, therefore, to investigate the long-term effect of dopaminergic 
medication on speech fluency in PD. Fourteen de novo PD patients with no history        
of developmental stuttering and 14 age- and sex-matched healthy controls (HC) were 
recruited. PD subjects were examined three times; before the initiation of dopaminergic 
treatment and twice in following 6 years. The percentage of dysfluent words was 
calculated from reading passage and monolog. The amount of medication was expressed 
by cumulative doses of L-dopa equivalent. After 3-6 years of dopaminergic therapy,  
PD patients exhibited significantly more dysfluent events compared to healthy subjects 
as well as to their own speech performance before the introduction of dopaminergic 
therapy (p < 0.05). In addition, we found a strong positive correlation between            
the increased occurrence of dysfluent words and the total cumulative dose of L-dopa 
equivalent (r = 0.75, p = 0.002). Our findings indicate an adverse effect of prolonged 
dopaminergic therapy contributing to the development of stuttering-like dysfluencies        
in PD. These findings may have important implication in clinical practice, where speech 
fluency should be taken into account to optimize dopaminergic therapy. 
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5.3. Acoustic Investigation of Stress Patterns in Parkinson’s Disease (A3) 
 
Authors and affiliations: 
Tereza Tykalová1, Jan Rusz1,2, Roman Čmejla1, Hana Růžičková2, Evžen Růžička2 
1Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical 
University in Prague 
2Department of Neurology and Centre of Clinical Neuroscience, First Faculty of 
Medicine, Charles University in Prague 
 
Journal, year of publication: Journal of Voice, 2014 
 
Journal statistics according to the Journal Citation Report® (2013): 
Impact factor: 0.944 
5-year impact factor: 1.208 
Category: Otorhinolaryngology 
Quartile in category: Q3 
 
Abstract: 
Although reduced stress is thought to be one of the most deviant speech dimensions         
in hypokinetic dysarthria associated with Parkinson’s disease (PD), the mechanisms       
of stress production in PD have not been thoroughly explored by objective methods. 
The aim of the present study was to quantify the effect of PD on prosodic characteristics 
and to describe contrastive stress patterns in parkinsonian speech. The ability of 20 male 
speakers with early PD and 16 age- and gender matched healthy controls (HC) to signal 
contrastive stress was investigated. Each participant was instructed to unnaturally 
emphasize five key words while reading a short block of text. Acoustic analyses were 
based on the measurement of pitch, intensity, and duration. In addition, an innovative 
measurement termed the stress pattern index (SPI) was designed to mirror the effect       
of all distinct acoustic cues exploited during stress production. Although PD patients 
demonstrated a reduced ability to convey contrastive stress, they could still notably 
increase pitch, intensity, and duration to emphasize a word within a sentence.                   
No differences were revealed between PD and HC stress productions using                      
the measurements of pitch, intensity, duration, and intensity range. However, restricted 
SPI and pitch range were evident in the PD group. A reduced ability to express stress 
seems to be the distinctive pattern of hypokinetic dysarthria, even in the early stages         
of PD. Because PD patients were able to consciously improve their speech performance 
using multiple acoustic cues, the introduction of speech therapy may be rewarding. 
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5.4. Effects of dopaminergic replacement therapy on motor speech disorders in 
Parkinson's disease: a longitudinal follow-up study on previously untreated 
patients (A4) 
 
Authors and affiliations: 
Jan Rusz1,2, Tereza Tykalová1,  Roman Čmejla1, Jiří Klempíř2, Evžen Růžička2 
1Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical 
University in Prague 
2Department of Neurology and Centre of Clinical Neuroscience, First Faculty of 
Medicine, Charles University in Prague 
3Institute of Anatomy, 1st Faculty of Medicine, Charles University in Prague 
 
Journal, year of publication: Journal of Neural Transmission, 2016 
 
Journal statistics according to the Journal Citation Report® (2015): 
Impact factor: 2.587 
5-year impact factor: 2.662 
Category: Clinical neurology / Neurosciences 
Quartile in category: Q2 / Q3 
 
Abstract: 
Although speech disorders represent an early and common manifestation of Parkinson’s 
disease (PD), little is known about their progression and relationship to dopaminergic 
replacement therapy. The aim of the current study was to examine longitudinal motor 
speech changes after the initiation of pharmacotherapy in PD. Fifteen newly-diagnosed, 
untreated PD patients and ten healthy controls of comparable age were investigated.         
PD patients were tested before the introduction of antiparkinsonian therapy and then 
twice within the following 6 years. Quantitative acoustic analyses of seven key speech 
dimensions of hypokinetic dysarthria were performed. At baseline, PD patients showed 
significantly altered speech including imprecise consonants, monopitch, inappropriate 
silences, decreased quality of voice, slow alternating motion rates, imprecise vowels and 
monoloudness. At follow-up assessment, preservation or slight improvement of speech 
performance was objectively observed in two thirds of PD patients within the first         
3-6 years of dopaminergic treatment, primarily associated with the improvement of stop 
consonant articulation. The extent of speech improvement correlated with L-dopa 
equivalent dose (r = 0.66, p = 0.008) as well as with reduction in principal motor 
manifestations based on the Unified Parkinson’s Disease Rating Scale (r = -0.61,           
p = 0.02), particularly reflecting treatment-related changes in bradykinesia but not        
in rigidity, tremor, or axial motor manifestations. While speech disorders are frequently 
present in drug-naive PD patients, they tend to improve or remain relatively stable        
after the initiation of dopaminergic treatment. 
19 
 
5.5. Speech disorders reflect differing pathophysiology in Parkinson’s disease, 
progressive supranuclear palsy and multiple system atrophy (A5) 
 
Authors and affiliations: 
Jan Rusz1,2, Cecilia Bonnet2,3, Jiří Klempíř2,4, Tereza Tykalová1, Eva Baborová2, Michal  
Novotný1, Aaron Rulseh5,6, Evžen Růžička2 
1Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical 
University in Prague;2Department of Neurology and Centre of Clinical Neuroscience, 
First Faculty of Medicine, Charles University in Prague; 3AP HP, Neurology 
Department, Pitie Salpetriere Hospital, Paris; 4Institute of Anatomy, 1st Faculty of 
Medicine, Charles University in Prague; 5Department of Radiology, Na Homolce 
Hospital, Prague; 6Department of Radiology, 1st Faculty of Medicine and General 
University Hospital, Charles University in Prague 
 
Journal, year of publication: Journal of Neurology, 2015 
 
Journal statistics according to the Journal Citation Report® (2014): 
Impact factor: 3.377 
5-year impact factor: 3.495 
Category: Clinical neurology 
Quartile in category: Q2 
 
Abstract: Although speech disorder is frequently an early and prominent clinical feature 
of Parkinson’s disease (PD) as well as atypical parkinsonian syndromes (APS) such as 
progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), there is         
a lack of objective and quantitative evidence to verify whether any specific speech 
characteristics allow differentiation between PD, PSP and MSA. Speech samples were 
acquired from 77 subjects including 15 PD, 12 PSP, 13 MSA and 37 healthy controls. 
The accurate differential diagnosis of dysarthria subtypes was based on the quantitative 
acoustic analysis of 16 speech dimensions. Dysarthria was uniformly present in                 
all parkinsonian patients but was more severe in PSP and MSA than    in PD. Whilst PD 
speakers manifested pure hypokinetic dysarthria, ataxic components were more affected 
in MSA whilst PSP subjects demonstrated severe deficits in hypokinetic and spastic 
elements of dysarthria. Dysarthria in PSP was dominated by increased dysfluency, 
decreased slow rate, inappropriate silences, deficits in vowel articulation and harsh 
voice quality whereas MSA by pitch fluctuations, excess intensity variations, prolonged 
phonemes, vocal tremor and strained-strangled voice quality. Objective speech 
measurements were able to discriminate between APS and PD with 95 % accuracy and 
between PSP and MSA with 75 % accuracy. Dysarthria severity in APS was related to 
overall disease severity (r = 0.54, p = 0.006). Dysarthria with various combinations           
of hypokinetic, spastic and ataxic components reflects differing pathophysiology in PD, 
PSP and MSA. Thus, motor speech examination may provide useful information           
in the evaluation of these diseases with similar manifestations. 
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5.6. Characteristics and occurrence of speech impairment in Huntington's disease: 
possible influence of antipsychotic medication. Journal of Neural Transmission 
(A6) 
 
Authors and affiliations: 
Jan Rusz1,2, Jiří Klempíř2, Tereza Tykalová1, Eva Baborová2, Roman Čmejla1,  Evžen 
Růžička2, Jan Roth2 
1Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical 
University in Prague 
2Department of Neurology and Centre of Clinical Neuroscience, First Faculty of 
Medicine, Charles University in Prague 
 
Journal, year of publication: Journal of Neural Transmission, 2014 
 
Journal statistics according to the Journal Citation Report® (2013): 
Impact factor: 2.871 
5-year impact factor: 2.862 
Category: Clinical neurology / Neurosciences 
Quartile in category: Q2 / Q3 
 
Abstract: 
Although motor speech impairment is a common manifestation of Huntington’s disease 
(HD), its description remains limited. The aim of the current study was therefore            
to estimate the occurrence and characteristics of speech disorder in HD and to explore 
the influence of antipsychotic medication on speech performance. Speech samples, 
including reading passage and monologue, were acquired from 40 individuals diagnosed 
with HD and 40 age- and sex-matched healthy controls. Objective acoustic analyses 
were used to evaluate key aspects of speech including vowel articulation, intensity, 
pitch and timing. A predictive model was constructed to detect the occurrence and most 
prominent patterns of speech dysfunction in HD. We revealed that 93 % of HD patients 
manifest some degree of speech impairment. Decreased number of pauses, slower 
articulation rate, imprecise vowel articulation and excess intensity variations were found 
to be the most salient patterns of speech dysfunction in HD. We further demonstrated 
that antipsychotic medication may induce excessive loudness and pitch variations 
perceptually resembling excess patterns of word stress, and may also accentuate general 
problems with speech timing. Additionally, antipsychotics induced a slight 
improvement of vowel articulation. Specific speech alterations observed in HD patients 
indicate that speech production may reflect the pathophysiology of the disease as well 
as treatment effects, and may therefore be considered a valuable marker of functional 
disability in HD. 
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5.7. Objective Acoustic Quantification of Phonatory Dysfunction in Huntington's 
Disease (A7) 
 
Authors and affiliations: 
Jan Rusz1,2, Jiří Klempíř2, Eva Baborová2, Tereza Tykalová1, Veronika Majerová2, 
Roman Čmejla1,  Evžen Růžička2, Jan Roth2 
1Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical 
University in Prague 
2Department of Neurology and Centre of Clinical Neuroscience, First Faculty of 
Medicine, Charles University in Prague 
 
Journal, year of publication: PLoS One, 2013 
 
Journal statistics according to the Journal Citation Report® (2012): 
Impact factor: 3.730 
5-year impact factor: 4.244 
Category: Multidisciplinary sciences 
Quartile in category: Q1 
 
Abstract: 
Although speech motor changes are reported as a common sign of Huntington’s disease 
(HD), the most prominent signs of voice dysfunction remain unknown. The aim of         
the current study was to explore specific changes in phonatory function in subjects        
with HD. 34 subjects with HD and 34 age- and sex-matched healthy controls were 
examined. Participants performed sustained vowel phonation for subsequent analyses of 
airflow insufficiency, aperiodicity, irregular vibrations of vocal folds, signal 
perturbations, increased noise, and articulation deficiency. In total, 272 phonations were 
collected and 12 voice parameters were extracted. Subsequently, a predictive model was 
built to find the most salient patterns of voice disorders in HD. The results were also 
correlated with disease severity according to the Unified HD Rating Scale (UHDRS) 
motor score. Subjects with HD showed deterioration in all investigated phonatory 
functions. Irregular pitch fluctuations, sudden phonation interruption, increased noise, 
and misplacement of articulators were found to be most significant patterns of 
phonatory dysfunction in HD (p < 0.001). The combination of these four dysphonia 
aspects contributed to the best classification performance of 94.1 % in the separation       
of HD patients from healthy participants. Our results further indicated stronger 
associations between sudden phonation interruption and voluntary components              
of the UHDRS (r = 20.48, p < 0.01) and between misplacement of articulators and 
involuntary components of the UHDRS (r = 0.52, p < 0.01). Our configuration               
of phonatory features can detect subtle voice abnormalities in subjects with HD.               
As impairment of phonatory function in HD was found to parallel increasing motor 
involvement, a qualitative description of voice dysfunction may be helpful to gain better 
insight into pathophysiology of the vocal tract. 
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5.8. Imprecise vowel articulation as a potential early marker of Parkinson’s disease: 
Effect of speaking task  (A8) 
 
Authors and affiliations: 
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Abstract: 
The purpose of this study was to analyze vowel articulation across various speaking 
tasks in a group of 20 early Parkinson’s disease (PD) individuals prior                       
to pharmacotherapy. Vowels were extracted from sustained phonation, sentence 
repetition, reading passage, and monologue. Acoustic analysis was based upon 
measures of the first (F1) and second (F2) formant of the vowels /a/, /i/, and /u/, vowel 
space area (VSA), F2i/F2u and vowel articulation index (VAI). Parkinsonian speakers 
manifested abnormalities in vowel articulation across F2u, VSA, F2i/F2u, and VAI            
in all speaking tasks except sustained phonation, compared to 15 age-matched healthy 
control participants. Findings suggest that sustained phonation is an inappropriate task 
to investigate vowel articulation in early PD. In contrast, monologue was the most 
sensitive in differentiating between controls and PD patients, with classification 
accuracy up to 80 %. Measurements of vowel articulation were able to capture even 
minor abnormalities in speech of PD patients with no perceptible dysarthria.                 
In conclusion, impaired vowel articulation may be considered as a possible early marker 
of PD. A certain type of speaking task can exert significant influence on vowel 
articulation. Specifically, complex tasks such as monologue are more likely to elicit 
articulatory deficits in parkinsonian speech, compared to other speaking tasks. 
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Abstract: 
Distinct speech characteristics that could help to differentiate between Parkinson's 
disease (PD), progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) 
are  tenaciously explored. The aim of the current study was to investigate the patterns 
and degree of consonant articulation deficits across voiced and voiceless stop plosives 
in 16 PD, 16 PSP, 16 MSA and 16 healthy control speakers using objective acoustic 
measures. The extent of consonant articulation deficits was more profound in PSP and 
MSA than in PD, although slight deterioration of consonant articulation was also 
observed in PD as compared to healthy speakers. In particular, voiceless plosives were 
found to be more prolonged in both PSP and MSA compared to PD, while voiced 
plosives were revealed to be significantly shorter only in MSA as a consequence of 
damage to the cerebellar structures. Detailed speech analysis may be diagnostically 
helpful in distinguishing between PD and atypical parkinsonian syndromes. 
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6. Summary of the achieved results and their contributions to the aims of 
the doctoral thesis 
 
In the following section, a brief list of the main results obtained along with their contributions 
to the goals of the doctoral thesis is provided. For more detailed discussion of results and their 
implications see the discussion sections of particular articles (A1-A8, B1). The results are 
organized according to the aims defined in chapter 3. 
 
1) To objectively quantify the effect of neurological disorder on speech production. 
 
 
 Using the appropriate speech parameters, methodology and evaluation criteria 
we managed to objectively quantify the effect of neurological disorder on speech 
production in PD (A2-A5, A8, B1), HD (A6, A7), APS (A5, B1) as well as CA 
(A1) patients. Furthermore, the combination of 4 dysphonia aspects enables the 
separation of HD patients from HC participants with the best classification 
performance of 94.1 ± 2.3 % (sensitivity of 95.1 ± 4.0 %; specificity of               
93.2 ± 4.3 %) (A7). The differentiation among several types of parkinsonian 
disorders is also possible, as documented in our study (A5) where using 
objective speech measurements we were able to discriminate between APS and 
PD with 95.3 ± 6.4 % accuracy (sensitivity of 93.4 ± 8.7 %; specificity of          
99.5 ± 4.1 %) as well as between PSP and MSA subjects with 75.2 ± 13.3 % 
accuracy (sensitivity of 74.3 ± 15.3 %; specificity of 81.2 ± 17.7 %) (A5).  
 
2) To design the feasible algorithms, methodologies or measurements that would be 
sensitive and accurate enough to capture pathological changes presented in particular 
speech dimensions.   
 
 As a part of our research (A3, A5, A7, A8, B1) several innovative algorithms, 
methodologies and measurements were designed to allow the evaluation of all 
speech aspects necessary for precise assessment of hypokinetic, hyperkinetic, 
spastic and ataxic components of dysarthria. For instance, we designed              
the algorithm for evaluation of articulation deficiency based on mel-frequency 
cepstral coefficients (A7), the methodology for assessment of vowel articulation 
from non-standardized connected utterances such as monolog (A8), or the 
measurement titled Stress Pattern Index designed to mirror the effect of all 
distinct acoustic clues exploited during word-stress production (A3). 
 
3) To relate the potentially observed speech changes to overall motor performance or 
medication doses in order to provide deeper insight into the pathophysiology of speech 
disturbances. 
 
 A number of correlations were found between clinical characteristics and 
speech parameters mainly in studies (A1, A2, A4-A7, B1). Considering PD,               
an adverse effect of prolonged dopaminergic therapy using L-dopa on speech 
fluency was found in PD patients after 3-6 years of taking medication (A2).         
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On the other hand, we found improved or maintained speech performances 
(related mainly to consonant and vowel articulation, pitch variability and 
number of pauses) in two-thirds of those PD patients whereas speech 
deteriorated only in one-third; indicating general positive effect of long-term 
dopaminergic therapy on MSD in early stages of PD (A4). The extent of speech 
improvement correlated with L-dopa equivalent dose (r = 0.66, p = 0.008)        
as well as with reduction in principal motor manifestations based on the Unified 
Parkinson’s Disease Rating Scale (r = -0.61, p = 0.02), particularly reflecting 
treatment-related changes in bradykinesia but not in rigidity, tremor, or axial 
motor manifestations (A4). Regarding HD, we observed that antipsychotic 
medication may induce excessive loudness and pitch variations and further 
exaggerated general problems with speech timing (A6). 
 
4) To critically discuss the revealed findings in the context of wide state-of-the-art.  
 
 Our findings especially contribute to clarification of previously published, 
highly inconsistent findings related to effect of long-term usage of dopaminergic 
medication on dysfluency (A2) as well as related to effect of dopaminergic 
medication of speech production in general (A4). With respect to dysfluency,        
we suggested based on our results that not only too high but also extremely low 
levels of dopamine may lead to different forms of dysfluent events including 
vocal blocks, prolongations and repetitions (A2). Regarding the effect of L-dopa 
on speech production in PD, we revealed that after initiation of therapy          
the speech is improved, however it is slightly continuously deteriorated within 
following several years, presumably due to disease progression (A4). Finally, 
we also unified the previous ambiguous findings related to duration of voice 
onset time, a commonly used parameter for evaluation of consonant 
articulation, as we suggested the potential relationship between 
increased/decreased values of voice onset time and particular voice onset time 
category (B1). 
 
5) To determine specific dysarthric patterns and estimate their reliability in differentiating 
between PD, PSP and MSA patients. 
 
 We found that PD speakers manifest pure hypokinetic dysarthria, whilst MSA 
speakers demonstrate predominant ataxic dysarthria and PSP speakers show 
severe deficits in both hypokinetic and spastic elements of dysarthria (A5). 
Moreover, the combination of five deviant speech dimensions (harsh voice, 
inappropriate silences, slow alternating motion rates, excess intensity variation 
and excess pitch variation) was able to separate PD from APS with a very high 
classification accuracy 95.3 ± 6.4 % (A5). Furthermore, the four deviant speech 
dimensions including harsh voice, fluency, slow rate and vocal tremor were able 
to discriminate PSP and MSA subjects with 75.2 ± 13.3 % accuracy (A5). From 
single parameters, consonant articulation of voiceless plosives turned out to be 
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the best for separation of APS from PD (p < 0.001) and consonant articulation 
of voiced plosives for differentiation between MSA and PSP (p < 0.01) (B1). 
 
6) To search for possible early markers of PD that would separate HC speakers from          
de-novo PD patients. 
 
 Using measurement of vowel articulation elicited from the speaking task           
of monologue, we were able to differentiate between controls and de-novo PD 
patients with classification accuracy up to 80 % (A8). Furthermore, we found     
a reduced ability to expressed contrastive word-stress in these patients (A3).  
 
7) To design innovative measurement that would reflect the effect of all main acoustic 
cues exploited during stress production. 
 
 A novel measurement termed Stress Pattern Index was designed and proved its 
feasibility for evaluation of prosodic changes in untreated de-novo PD patients 
(A3). 
 
8) To design methodology for evaluation of imprecise vowel articulation based on 
spontaneous speech such as monologue. 
 
 An innovative 6-step methodology for vowel selection from spontaneous speech 
and determination of formant frequencies from these vowels was established 
(A8). The methodology was tested for measurement reliability and showed           
to have high intra- as well as inter-judge reliability (r = 0.93-0.99, p < 0.001). 
Although it has been originally designed based on de-novo PD patients database 
(A8), it has also been successfully used for evaluation of imprecise vowel 
articulation in MSA, PSP, HD and CA patients (A1, A5, A6).   
 
9) To investigate the effect of different speaking tasks on assessment of vowel articulation. 
 
 Four speaking tasks including sustained phonation, sentence repetition, reading 
passage and monologue were compared in order to test their suitability            
for capturing subtle alterations in vowel articulation of de-novo PD patients 
(A8). In summary, sustained phonation was found to be inappropriate speaking 
task for investigation of deficits in vowel articulation in early PD (A8). 
Contrary, monolog was the most sensitive in differentiating between controls 
and de-novo PD patients with high classification accuracy up to 80 % (A8). 
 
10) To examine the effectiveness of a 2-week intensive coordinative motor training on 
speech production in CA patients. 
 
 We found that 12-day rehabilitative program had a mild beneficial effect on 
speech in CA patients (A1). Immediately after the last training session, slight 
improvements in overall speech performance were evident in all 10 patients 
(A1). Furthermore, follow-up assessment performed 4 weeks later revealed that 
speech improvements were maintained in 90 % of the patients (A1). 
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7. Conclusion 
 
Using innovative methods of acoustic analysis it is possible to objectively quantify the effect 
of different neurological disorders on speech production in patients with various medical 
diagnoses and disease severities. In particular, we were able to assess a number of speech 
aspects belonging to different dysarthria subtypes including hypokinetic, hyperkinetic, ataxic 
and spastic in subjects with PD, HD, MSA, PSP and CA. Furthermore, we managed to detect 
subtle speech changes related to articulation and contrastive stress production in untreated         
de-novo PD patients, i.e. patients recorded at the time of the diagnosis before the symptomatic 
treatment was established. Based on our findings and since each neurologic disease affects 
speech in a manner that reflects its localization and underlying pathophysiology, we believe 
that recognition, evaluation and classification of speech disturbances can significantly 
contribute to early and correct diagnosis of the particular disorder. 
 Additionally, acoustic analyses of MSD can provide more insights into underlying 
pathophysiology of such diseases as clearly documented in our study focused on evaluation  
of speech dysfluencies in PD, where the hypothesis about the connection of stuttering-like 
behaviour with reduced level of dopamine within the basal ganglia circuit has been at least 
partially supported.  
 Finally, accurate evaluation and monitoring of speech abnormalities may be helpful       
in assessment of treatment efficiency, providing feedback to patients during speech therapy  
or assist clinicians in making different management decisions. With respect to this goal,      
we also performed some preliminary experiments as a part of this thesis as we assessed       
the effect of motor coordinative training in CA patients. 
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8. Future work 
 
Future research should confirm our previous findings, extend and validate the reliability        
of algorithms, methodologies and measurements applied for acoustic analysis and further test 
the potential of objective speech evaluation to serve as a tool for establishing of early 
diagnosis, separating between different neurological diseases with similar initial clinical 
symptoms or providing feedback to patients and clinicians during speech therapy. 
 It would be desirable to verify our previous findings using large homogenous 
databases, ideally accompanied by other clinical examinations such as functional magnetic 
imaging resonance or positron emission tomography, since most of our studies (A1-A5, A8, 
B1) have rather character of pilot studies with datasets counting 10-25 subjects in each 
patient's group. The large sample sizes would further allow splitting of patients into more 
specific groups, for instance, according to predominance of motor manifestations (PD tremor 
dominant vs. PD akinetic-rigid dominant) or disease subtypes (MSA-cerebellar type vs.  
MSA-parkinsonian type). Research based on such databases is likely to significantly 
contribute mainly to our knowledge regarding underlying speech-related pathophysiologic 
mechanisms of studied disorders. 
 In classical study by Duffy (1), the classification of dysarthria subtypes (ataxic, 
spastic, hypokinetic, hyperkinetic vs. flaccid) was based on perceptual evaluation of more 
than 50 different distinguishing speech aspects. However, we are currently capable to 
precisely objectively quantify only a small proportion of them. Thus, it is necessary to further 
extend, optimise and validate the existing algorithms and methodologies for evaluation         
of particular speech aspects and to develop novel acoustic measurements for speech aspects 
whose evaluation is currently based solely on perceptual methods. 
 As an example, the speech dimension of reduced stress might be used. Recently,       
the ability to express word-stress was assessed mainly by perceptual assessments (1) while      
it has been already shown that changes in expression of word-stress can also been captured by 
acoustic parameters such as modification of pitch, intensity or duration (74, 75). As a part       
of this thesis, a novel measurement termed Stress Pattern Index which mirrors the alterations      
in all these prosodic parameters was designed and proved to be suitable for evaluation                 
of reduced stress in untreated de-novo PD patients (A3). Yet, the feasibility of this 
measurement needs to be tested for patients with lower or more severe speech severity as well 
as for different CNS disorders where the disturbed ability to express linguistic stress might be 
anticipated. In addition, the acoustic analyses are currently only partially automated as they 
still demand manual control of process. It would be also useful to manage to evaluate the 
ability to express word-stress from some non-specialized speaking task such as monologue. 
 To ensure that the measured speech alterations in particular subject are genuinely the 
result of underlying neuropathological processes, it is essential to know what effect might 
have the second repetition of speaking task by same person (test-retest) on measurement       
of individual speech aspect and in what range the performance of HC speakers might be 
expected. To this extent, the longitudinal studies, monitoring and recording the same patients 
for several years, should be carried out to test the sensitivity of acoustic measurements and        
to confirm the previously observed trend in worsening of speech performances due to disease 
progression. Furthermore, the acoustic investigation of speech performances using large 
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dataset of HC speakers should be performed to define the effect of age and gender                    
on particular speech parameters. In fact, the natural changes of voice and speech 
performances in HC population are presented as a consequence of normal aging process      
due to changes in anatomy and physiology of the speech mechanism, reduced sensory 
feedback or decreased speed/accuracy of motor control (76, 77). However, such changes are 
not pathological in its origin and their effects have to be known and well-defined. 
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